1887
6 The Anbar 2nd International Medical Conference (AIMCO 2022)
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

Abnormalities in liver function tests (LFTs) are found in 14%–53% of hospitalized COVID-19 patients. These could occur in patients with or without previous chronic liver diseases. Knowing the risk factor of liver manifestations in COVID-19 subjects is crucial for the proper management of these patients.

We aimed to identify the risk factors for liver manifestations as well as other risk factors in COVID-19 subjects who complained of digestive manifestations.

COVID-19 patients with and without liver manifestations at the Emergency Department of Al Fallujah Teaching Hospital were enrolled in this study. This study covered a period from September 15, 2022, to April 22, 2022. Comparisons between patients with or without abnormal LFTs were made. The possible risk variables connected to abnormal LFTs and hepatic manifestation were investigated using univariable and multivariable logistic regression analysis.

Out of 100 COVID-19 patients, there were 64 suffering from mild gastrointestinal (GI) symptoms. There were 26 mild cases with abnormal LFTs (40.6%). Although there were nine (total number 22) and seven (total number 14) of the moderate and severe cases with liver involvement, there was no statistically significant difference between the digestive manifestations severity and liver involvement. Increased alanine aminotransferase (ALT) levels were linked to a greater incidence of LFTs, according to multivariable analysis (odds ratio [OR]: 45.05; < 0.0001), elevated aspartate aminotransferase (AST; OR: 3.462; = 0.00041), elevated direct bilirubin (DBIL) (OR: 3.643; < 0.001), and elevated d-dimer levels [OR]: 2.690; < 0.0137) in liver involvement group compared with non-involvement patients.

Elevated ALT, AST, DBIL, and d-dimer are potential risk factors for liver manifestations in COVID-19 patients with digestive symptoms.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2022.aimco.11
2022-12-06
2023-02-09
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2022/6/jemtac.2022.aimco.11.html?itemId=/content/journals/10.5339/jemtac.2022.aimco.11&mimeType=html&fmt=ahah

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New Eng J Med. 2020; 382:(8):727–33.
    [Google Scholar]
  2. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581:(7807):215–20.
    [Google Scholar]
  3. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New Eng J Med. 2020; 382:(18):1708–20.
    [Google Scholar]
  4. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115:(5):766–73.
    [Google Scholar]
  5. Al-Ani RM, Rashid RA. Prevalence of dysphonia due to COVID-19 at Salahaddin General Hospital, Tikrit City, Iraq. Am J Otolaryngol. 2021; 42:(5):103157.
    [Google Scholar]
  6. Yaseen NK, Al-Ani RM, Rashid RA. COVID-19-related sudden sensorineural hearing loss. Qatar Med J. 2021; 2021:(3):58.
    [Google Scholar]
  7. Al-Ani RM. Smell and taste abnormalities due to COVID-19. Al-Anbar Med J. 2020; 16:(1):1–2.
    [Google Scholar]
  8. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020; 73:(3):566–74.
    [Google Scholar]
  9. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnor-mality. Clin Gastroenterol Hepatol. 2020; 18:(7):1561–6.
    [Google Scholar]
  10. Li P, Liu Y, Cheng Z, Yu X, Li Y. COVID-19-associated liver injury: clinical characteristics, pathophysiological mechanisms and treatment management. Biomed Pharmacother. 2022; 154::113568.
    [Google Scholar]
  11. Feng G, Zheng KI, Yan Q-Q, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current in-sights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020; 8:(1):18.
    [Google Scholar]
  12. Mao R, Qiu Y, He J-S, Tan J-Y, Li X-H, Liang J, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5:(7):667–78.
    [Google Scholar]
  13. Leung JM, Yang CX, Sin DD. Reply to: “Current smoking is not associated with COVID-19”. Eur Respir J. 2020; 55:(6).
    [Google Scholar]
  14. Ding S, Liang TJ. Is SARS-CoV-2 also an enteric pathogen with potential fecal–oral transmission? A COVID-19 virological and clinical review. Gastroenterology. 2020; 159:(1):53–61.
    [Google Scholar]
  15. Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diag-nosis, and treatment. Cureus. 2020; 12:(3):e7355.
    [Google Scholar]
  16. Fosbøl EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020; 324:(2):168–77.
    [Google Scholar]
  17. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309:(5742):1864–8.
    [Google Scholar]
  18. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol. 2020; 92:(10):1733–4.
    [Google Scholar]
  19. Lim MA, Pranata R, Huang I, Yonas E, Soeroto AY, Supriyadi R. Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis. Can J Kidney Health Dis. 2020; 7::2054358120938573.
    [Google Scholar]
  20. Lippi G, de Oliveira MHS, Henry BM. Chronic liver disease is not associated with severity or mortality in Corona-virus disease 2019 (COVID-19): a pooled analysis. Eur J Gastroenterol Hepatol. 2021; 33:(1):114–5.
    [Google Scholar]
  21. Wu P, Hao X, Lau EH, Wong JY, Leung KS, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020; 25:(3):2000044.
    [Google Scholar]
  22. Jasim MA, Ghazzay H, Noaman H, Khalil M, Johna S. The outcome of telemedicine services for COVID-19 pa-tients in “Al-Anbar” province west of Iraq. J Emerg Med Trauma Acute Care. 2021; 2021:(3):16.
    [Google Scholar]
  23. Ghazzay H, Al-Ani RM, Khalil MA, Hammad AF. Socio-clinical characteristics of COVID-19 disease in Anbar Gov-ernorate, Iraq. J Emerg Med Trauma Acute Care. 2021; 2021:(1):8.
    [Google Scholar]
  24. Hassan BM, Khalil MA, Abdulhameed RA, Al-Anbari AJK. A comparative study on the chest CT scan radiological findings and hematological parameters of COVID–19 and non–COVID-19 pneumonia patients in Al-Yarmouk Teaching Hospital in Baghdad, Iraq. Medico-Legal Update. 2020; 20:(4):833–40.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jemtac.2022.aimco.11
Loading
/content/journals/10.5339/jemtac.2022.aimco.11
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error